Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
J Tuñón, PG Steg, ODYSSEY OUTCOMES Investigators et al.
KEYWORDS
chronic kidney disease; glomerular filtration rate; Low-density lipoprotein cholesterol; MACE; PCSK9 inhibition